In melanoma, colon and breast murine cancer cells, the inhibition of PCSK9 synergistically boosted the tumor response to murine anti-PD1 immune checkpoint inhibitor, resulting in the suppression of tumor growth. This evidence concerns the gene PCSK9 and neoplasm.